12 months from date of receipt / reconstitution, -20 °C as supplied
| 应用 | 稀释度 | 推荐种属 |
|---|---|---|
| WB | 1:1000 | Hu |
CD3L1 (CD3 ligand 1), also known as ITPRIPL1, is the first identified ligand of CD3 and plays a crucial role in tumor immune evasion and testicular immune privilege. CD3L1 inhibits T-cell activation by directly binding to CD3ε, a process that involves the sustained binding of Nck to the intracellular domain of CD3ε, competitively inhibiting the recruitment and phosphorylation of Zap70, thus suppressing T-cell activation at the initial stage. This discovery reveals the existence of a natural ligand for CD3, suggesting that the TCR/CD3 complex may not be regulated in a TCR-dominant "monopolar" manner but rather in a "bipolar" mode where both TCR and CD3 have natural regulatory ligands. The identification of CD3L1 offers a new target for cancer immunotherapy and promises to bring new breakthroughs in the field.
WB result of CD3L1 (ITPRIPL1) Recombinant Rabbit mAb
Primary antibody: CD3L1 (ITPRIPL1) Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: HeLa whole cell lysate 20 µg
Lane 2: Raji whole cell lysate 20 µg
Lane 3: HCT 116 whole cell lysate 20 µg
Lane 4: A375 whole cell lysate 20 µg
Negative control: HeLa whole cell lysate
Secondary antibody: Goat Anti-Rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 63 kDa
Observed MW: 55 kDa
This blot was developed with high sensitivity substrate
您现在的位置：